Health
FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.
OriginalSourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityPublished20:18 UTCRatings: AllSides, MBFCSourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityPublished20:18 UTCRatings: AllSides, MBFC
“FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications”
“The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels”
FDA warns of rare eye condition NAION linked to GLP-1 meds
Key points
- FDA requires all GLP-1 medications to include NAION risk on labels.
- NAION can cause sudden, painless vision loss and permanent blindness.
- Study data show higher NAION incidence in GLP-1 users than controls.
- FDA reviewed 126 trials with over 134,200 patients to assess risk.
- Pharma firms defend benefit-risk profile while monitoring safety and comment.
Other reports
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
- SourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at MintSourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at Mint
- SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars TechnicaSourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica
“GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns”
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The NationalSourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The National
“FDA orders new warning on GLP-1 drugs over potential risk of blindness”
- SourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global NewsSourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global News
- SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBCSourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
“Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness”
- SourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLineSourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLine
“FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning”
How it got here
The Guardian publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 8.
The Brief ranks it 8th.
8 8 FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.